The challenge of herbal therapies for prostate cancer

Clinical Cancer Research

Volumn 14, Issue 23, 2008, Pages 7581-7582

  Bhatt, Rupal S ^a   Bubley, Glenn J ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; PC SPES; PROBASIN; SILIBININ; WARFARIN; ANTINEOPLASTIC AGENT; SILYMARIN;

ANTIANGIOGENIC ACTIVITY; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; GYNECOMASTIA; HERBAL MEDICINE; HUMAN; NONHUMAN; NOTE; PRIORITY JOURNAL; PROSTATE CANCER; THROMBOSIS; ANIMAL; MALE; MOUSE; PHYTOTHERAPY; PROSTATE TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; MALE; MICE; PHYTOTHERAPY; PROSTATIC NEOPLASMS; SILYMARIN;

EID: 59449101522     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2316     Document Type: Note

References (13)

1. Singh RP, Raina K, Sharma G, Agarwal R. Silibinin inhibits established prostate tumor growth, progression, invasion and metastasis, and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res 2008;7773-80.
2. Yannucci J, ManolaJ,Garnick MB, BhatG,BubleyGJ.The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol 2006;176:520-5.
3. Smith MR. Androgen deprivation therapy and risk for diabetes and cardiovascular diseasein prostatecancer survivors. Curr Urol Rep 2008;9:197-202.
4. Oh WK, Kantoff PW, Weinberg V, et al. Prospective, multicenter, randomized phase II trial of the herbal supplement,PC-SPES,and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol 2004;22:3705-12.
5. Small EJ, Frohlich MW, Bok R, et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol. 2000;18:3595-603.
6. Clement J, Bubley G. Prostasol and venous thromboembolism. Urology 2008;72:664-6.
7. Raina K, Rajamanickam S, Singh RP, DeepG, Chittezhath M, Agarwal R. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostatemodel. Cancer Res 2008;68:6822-30.
8. Yoshida H, Broaddus R, Cheng W, Xie S, Naora H. Deregulation of the HOXA10 homeobox gene in endometrial carcinoma: role in epithelial-mesenchymal transition. Cancer Res 2006;66:889-97.
9. Li L, GaoY, Zhang L, Zeng J, He D, Sun Y. Silibinin inhibits cell growth and induces apoptosis by caspase activation, down-regulating survivin and blocking EGFR-ERK activation in renal cell carcinoma. Cancer Lett 2008.
10. SinghRP,TyagiA, SharmaG,Mohan S, Agarwal R. Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down-regulation of survivin. Clin Cancer Res 2008;14:300-8.
11. Shariat SF, Karam JA,WalzJ, et al. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based bio-markers. Clin Cancer Res 2008;14:3785-91.
12. De Cicco C, Ravasi L, Zorzino L, et al. Circulating levels of VCAM and MMP-2 may help identify patients with more aggressive prostate cancer. Curr Cancer DrugTargets 2008;8:199-206.
13. GeorgeDJ,Regan MM,OhWK,etal. Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. Urology 2004;63:327-32.